NAC in MyoBalan: Cysteine Supply and Glutathione Study Limits
TL;DR:
- MyoBalan declares 100 mg NAC per three-capsule daily serving; this is a label fact, not a glutathione outcome.
- NAC can supply cysteine, but cellular glutathione synthesis depends on more than the presence of one precursor.
- The cited human studies used different NAC amounts and populations, so their results cannot be assigned to MyoBalan.
MyoBalan lists 100 mg of N-acetyl-L-cysteine, usually shortened to NAC, for its full three-capsule daily serving. That number identifies an ingredient amount. It does not show how much cysteine reaches a particular tissue, how much glutathione will be produced or whether the complete formula changes a health outcome.
NAC is often discussed as a cysteine source because cysteine participates in glutathione synthesis. The pathway is real, but the conclusion must stay proportionate to the evidence. This guide separates the verified MyoBalan label from findings in human studies that used larger NAC amounts and different participant groups.
Table of Contents
- Start With the Serving
- From NAC to Cysteine
- Glutathione Is a Pathway, Not a Label Claim
- Compare the Study Before Borrowing Its Result
- Keep the Formula Together
- Build an Evidence Note
Key Takeaways
| Question | What the evidence can answer |
|---|---|
| What does MyoBalan contain? | The current market-specific label |
| Why is NAC linked with cysteine? | Biochemistry and pharmacokinetic evidence |
| Did a human study find a change? | Only for its tested dose, duration and participants |
| Will MyoBalan produce the same result? | Not established by those ingredient studies |
Start With the Serving
The current MyoBalan France product information describes a 90-capsule pack and directs three capsules daily with water. The primary France label gives NAC as 100 mg for those three capsules. Reading the serving first prevents a common error: treating the daily amount as though it applied to each capsule.
The same panel lists 1,500 mg myo-inositol and 37.5 mg D-chiro-inositol, a declared 40:1 ratio, plus 100 mg ubiquinone CoQ10, zinc, vitamin D3, L-methylfolate and piperine. NAC therefore sits within a multi-ingredient serving. It should not be assessed as if the product were a standalone NAC tablet.
The selected variant was ACTIVE but unavailable when checked on 20 September 2026, with inventory at zero and a deny policy. The link is supplied for product identity and current information. It is not a stock promise or a reason to substitute another market version without checking its own panel.
From NAC to Cysteine
NAC is an acetylated form related to the amino acid cysteine. After oral administration, its handling includes absorption, distribution and deacetylation. The phrase “cysteine precursor” describes that relationship; it does not supply a universal conversion percentage for a capsule label.
A phase I pharmacokinetic study by Papi and colleagues gave healthy Chinese and Caucasian volunteers 600 mg oral NAC as a single dose and then twice daily for three days. Plasma NAC rose rapidly, with a reported peak around one hour, and the study compared exposure between the two cohorts. MyoBalan was not used.
That study helps show why an ingredient does not move directly from label to cellular outcome. Researchers measured NAC after a defined 600 mg intervention, under a defined schedule, in 30 healthy adults. MyoBalan's label declares 100 mg in a different product. The six-fold amount difference for a single study dose is a boundary, not a scaling instruction.
Pharmacokinetics also does not equal efficacy. Detecting or estimating an ingredient's exposure can inform what the body encounters, but it does not prove that a downstream biomarker or subjective outcome will change. Each additional conclusion needs its own measurement.
Glutathione Is a Pathway, Not a Label Claim
Glutathione is synthesized from cysteine, glutamate and glycine through enzyme-controlled steps. Cysteine availability can be limiting in some settings, which explains scientific interest in NAC. Yet a pathway contains substrates, enzymes, compartments and regulatory conditions. Listing one precursor does not reveal the rate of the whole pathway in an individual.
A randomized supplementation study by Borges-Santos and colleagues compared seven days of 1 g daily NAC with glutamine in 12 treated HIV-positive participants and 20 healthy controls. The groups differed at baseline, and the investigators measured plasma amino acids and glutathione-related markers. Their NAC arm increased cysteine and glutathione measures in that specific design.
The result is useful for understanding precursor supply in a studied population. It is not evidence that 100 mg NAC inside MyoBalan produces the same change. The amount was ten times higher, the participant characteristics were specific, and the intervention was studied separately rather than as this eight-active formula.
Biomarkers also require careful naming. Plasma glutathione is not a direct readout of every cellular compartment. A change in one sampled compartment should not be rewritten as a whole-body outcome or a product benefit. Record the sample, marker, time point and population together.
Compare the Study Before Borrowing Its Result
A second example makes the transfer problem clearer. A placebo-controlled randomized crossover trial by Treweeke and colleagues studied oral NAC in 14 people with type 2 diabetes. Participants received 1,200 mg, and investigators assessed intraplatelet glutathione and platelet-monocyte conjugation.
That trial tested a population with a diagnosed condition, a dose twelve times the MyoBalan NAC line and outcomes that are not part of this product's label. It cannot be used to claim a result for women generally, for reproductive health or for the finished formula. It can instead teach the fields that must match before evidence transfer is considered.
Use a five-column check: intervention, amount, participants, duration and outcome. Add a sixth column for the finished product. If the study used standalone NAC and the label describes a multi-ingredient product, write that mismatch down rather than hiding it behind a shared ingredient name.
Do not average results from unrelated trials to create a number for MyoBalan. Nor should a mechanistic diagram be treated as a substitute for a human finished-product study. The appropriate conclusion may be that the pathway is relevant while a product-specific outcome remains untested.
Keep the Formula Together
The current France panel gives the complete daily serving as myo-inositol 1,500 mg; D-chiro-inositol 37.5 mg; ubiquinone CoQ10 100 mg; NAC 100 mg; zinc 10 mg; vitamin D3 25 micrograms; L-methylfolate 200 micrograms; and piperine 5 mg. The piperine is declared as coming from black pepper fruit extract, but the label does not state the total mass of that extract.
Increasing the capsule count to imitate a standalone NAC study would increase every one of these entries and exceed the labeled direction. A study-dose comparison is an evidence boundary, never a dosing calculator. Follow the current pack and ask a qualified professional about personal circumstances.
The label is for adults, says the product is not recommended during pregnancy or breastfeeding, and advises consulting a doctor or pharmacist when taking medication. It also says not to exceed the recommended daily amount and that supplements do not replace a varied, balanced diet and healthy lifestyle.
No named allergen declaration was found in the primary label checked. That absence is not an allergen-free statement. If allergy, medication use or a medical condition affects the decision, obtain current pack-specific information and professional advice rather than inferring suitability from an ingredient mechanism.
Build an Evidence Note
A useful product note can be short: “MyoBalan France, three capsules daily, NAC 100 mg, multi-ingredient formula, variant unavailable on 20 September 2026.” Attach the current label or clear photographs. Keep stock status as a dated observation because it can change.
For each study, record the NAC amount, schedule, population, comparator and measured outcome. Then add a transfer line: “Not MyoBalan; amount and formula differ.” This prevents a true study result from being turned into an unsupported product promise when notes are copied later.
The strongest reading is often the most limited one. MyoBalan contains a verified amount of NAC, NAC has a documented relationship to cysteine supply, and human studies have examined NAC under other conditions. Those three statements can coexist without claiming that this product reproduces those studies.
Frequently Asked Questions
How much NAC does MyoBalan declare?
The verified France label lists 100 mg of N-acetyl-L-cysteine for the full daily serving of three capsules. It is one component of an eight-active formula, not 100 mg per capsule.
Does NAC automatically raise glutathione in everyone?
No. NAC can provide cysteine, but a precursor relationship is not a guaranteed individual response. Glutathione synthesis, distribution, baseline status, dose, duration and the measured tissue all matter.
Were the cited NAC studies conducted on MyoBalan?
No. They tested oral NAC as a separate intervention in different populations and at amounts from 600 mg to 1,200 mg or 1 g daily. None tested this finished formula or its 100 mg NAC entry.
Can I take more MyoBalan to match a study dose?
No. The label says three capsules daily. Increasing the product would also increase myo-inositol, D-chiro-inositol, CoQ10, zinc, vitamin D, methylfolate and piperine, and would exceed the labeled direction.
What should I check before considering the product?
Match the current market pack, read the complete formula and warnings, and discuss medication or pregnancy questions with a qualified professional. The selected France variant was unavailable on 20 September 2026, and no allergen-free assurance is made.
Recommended
- MyoBalan: reading the CoQ10 ubiquinone evidence
- Glucorine: keeping label references separate from requirements
- Kailuxe: checking nutrient overlap across a routine
- ReishiNova: product identity and evidence documentation
- Review the current MyoBalan product information
Our research and formulas have been recognized by leading media outlets such as Marie Claire.
Scientific References
- Papi et al. (2021): oral NAC pharmacokinetics in healthy Chinese and Caucasian volunteers
- Dröge et al. (2012): cysteine or glutamine supplementation and plasma glutathione in HIV-positive participants and healthy controls
- Gibson et al. (2012): randomized crossover NAC study in participants with type 2 diabetes
These statements have not been evaluated by the Food and Drug Administration. BioEssentials products are food supplements intended to support general wellness and daily nutritional needs. They are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any new supplement if you are pregnant, breastfeeding, taking medication, or managing a health condition.
